CMTA’s latest analysis reveals 135 genes and 169 subtypes driving CMT. It offers new insights into the complexity, classification, and future of genetic discovery. Read the story behind the headlines.
CMTA-STAR Partner Applied Therapeutics Presents 24-Month CMT-SORD Data at PNS 2025
CMTA-STAR Alliance Partner Applied Therapeutics presented 24-month Phase III data on govorestat for CMT-SORD at PNS 2025, showing sustained clinical benefit, MRI-based disease slowing, and continued safety. These findings support the potential for the first approved treatment for CMT-SORD and mark progress toward an expected NDA submission.
